SME · NSE EmergeListed

Avience Biomedicals Ltd. IPO: dates, price band, lot size, objects of the issue

Get analyst updates on this IPO

Analyst updates come by email.

What changed since listing, from SEBI-registered research analysts.

By continuing you agree to the Terms and Privacy policy

Updated Tue 17 Nov 2026, 10:51 am IST · Source: Prospectus dated Tue 23 Jun 2026

Bid dates
Thu 18 Jun 2026 to Mon 22 Jun 2026
Listing date
Thu 25 Jun 2026
Issue price
₹208 per share

Listed on NSE on Thu 25 Jun 2026.

Listing price ₹395.20

Opening price on NSE on the listing day (ipocentral.in, as of Tue 17 Nov 2026)

This page is now frozen. Facts stay as filed; the quote is on the exchange.

Key facts

Issue price
₹208 per share
Prospectus dated Tue 23 Jun 2026, page 3
Lot size
600 shares
Prospectus dated Tue 23 Jun 2026, page 9
Issue size at the upper band
₹30.24 crore
Fresh issue
₹30.24 crore
Prospectus dated Tue 23 Jun 2026, page 1
Offer for sale
None
Prospectus dated Tue 23 Jun 2026, page 1
Bid dates
Thu 18 Jun 2026 to Mon 22 Jun 2026
Prospectus dated Tue 23 Jun 2026, page 1
Listing date
Thu 25 Jun 2026
Prospectus dated Tue 23 Jun 2026, page 429
Anchor lock-in ends
Not stated in the prospectus
Prospectus dated Tue 23 Jun 2026
Risk factors
94
Prospectus dated Tue 23 Jun 2026, page 63

Timeline (IST)

  1. OpensThu 18 Jun 2026, 10:00 am IST confirmedProspectus dated Tue 23 Jun 2026, page 1
  2. ClosesMon 22 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 1
  3. UPI mandate cut-offMon 22 Jun 2026, 5:00 pm IST confirmedProspectus dated Tue 23 Jun 2026, page 1
  4. AllotmentTue 23 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
  5. Refund and unblockWed 24 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
  6. Shares to dematWed 24 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429
  7. ListingThu 25 Jun 2026 confirmedProspectus dated Tue 23 Jun 2026, page 429

Objects of the issue

ObjectAmount
Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh₹14.05 crore
Funding the working capital requirement of our Company₹8.25 crore
General Corporate Purposes₹3.97 crore
Total₹26.27 crore

Prospectus dated Tue 23 Jun 2026, page 99

Company and promoters

As described in the prospectus

Avience Biomedicals has expanded its product range from IVD rapid test kits to include a comprehensive line of medical devices such as Serology products, Biochemistry Analyser and Biochemistry Reagents, showcasing a dedication to addressing various healthcare needs.

Prospectus dated Tue 23 Jun 2026, page 23

Promoters

  • 4 individual promoters

Prospectus dated Tue 23 Jun 2026, page 23

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group87.89%64.59%

Prospectus dated Tue 23 Jun 2026, page 93

Financials (restated)

ItemJanuary 31, 2026March 31, 2025March 31, 2024
Revenue from operations₹41.84 crore₹45.24 crore₹23.96 crore
Profit after tax₹5.74 crore₹7.23 crore₹2.14 crore
Net worth₹28.52 crore₹22.78 crore₹6.21 crore
Total borrowings₹26.73 crore₹22.16 crore₹15.13 crore

Prospectus dated Tue 23 Jun 2026, page 67

Risk factors

94 total
  1. The company operates in a heavily regulated market and failing to comply with rules could lead to litigation or other liabilities (offer document page 33)
  2. A portion of revenue comes from a few customers, and losing a major customer could hurt the business (offer document page 33)
  3. The company relies on outside suppliers for trading goods and for raw materials and components, and supply disruptions could hurt operations (offer document page 34)
  4. The business needs a large amount of working capital, and not meeting that need could hurt results (offer document page 36)
  5. Some raw materials are imported from China, so import restrictions or duties could affect the business (offer document page 37)

All 94 risk factors, pages 32 to 63

Offer document

Allotment and bids

Registrar to the issue: SKYLINE FINANCIAL SERVICES PRIVATE LIMITED.

Allotment status is on the registrar's site, from Tue 23 Jun 2026. Pick "Avience Biomedicals Ltd." from the issue list there.

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts